AS-136A

CAS No. 949898-66-2

AS-136A( —— )

Catalog No. M35620 CAS No. 949898-66-2

AS-136A is an orally active measles virus RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that inhibits measles virus and blocks viral RNA synthesis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AS-136A
  • Note
    Research use only, not for human use.
  • Brief Description
    AS-136A is an orally active measles virus RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that inhibits measles virus and blocks viral RNA synthesis.
  • Description
    AS-136A is an orally active non-nucleoside inhibitor of the measles virus RNA-dependent RNA polymerase (RdRp) with an IC50 of 2 μM for measles virus.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA/RNA Synthesis
  • Recptor
    DNA/RNA Synthesis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    949898-66-2
  • Formula Weight
    416.42
  • Molecular Formula
    C17H19F3N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=CC=C(C=C1)S(=O)(=O)N2CCCCC2)C3=CC(=NN3C)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ndungu JM, et al. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics. J Med Chem. 2012;55(9):4220-4230.?
molnova catalog
related products
  • DDRI-18

    DDRI-18 is a novel small molecule inhibitor that regulates the DNA damage response with sensitizing and anticancer activities, inhibits non-homologous end-joining (NHEJ) DNA repair and enhances the cytotoxicity of anticancer DNA damage compounds.

  • VVD-214

    VVD-214 (RO7589831) is a WRN deconjugating enzyme lethal variant inhibitor with potential antitumor activity, inhibits ATP hydrolysis and deconjugating enzyme activity, and can be used in the study of proliferative diseases.

  • Piboserod

    Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.